» Articles » PMID: 18753332

Functional Expression of CXCR4 in Somatotrophs: CXCL12 Activates GH Gene, GH Production and Secretion, and Cellular Proliferation

Overview
Journal J Endocrinol
Specialty Endocrinology
Date 2008 Aug 30
PMID 18753332
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The interaction of chemokine (C-X-C motif) ligand 12 (CXCL12) and its receptor CXCR4 may play an important role in the regulation of anterior pituitary function. In this study, we investigated the expression of CXCL12 and CXCR4 and their role in normal rat pituitary and GH-producing GH3 tumor cell line. RT-PCR analysis and immunohistochemistry revealed that CXCR4 was expressed in normal rat anterior pituitary and GH3 tumor cells. Double immunofluorescent staining showed the complete colocalization of CXCR4 with GH in rat pituitary, indicating that CXCR4 is specifically expressed in rat somatotrophs. Using rat primary pituitary cell cultures and GH releasing hormone receptor expressing stable GH3 cells (GH3-GHRHR), we evaluated the function of CXCL12 compared with GHRH. CXCL12 stimulated GH gene activation in both primary rat anterior pituitary cells and GH3-GHRHR cells. CXCL12 also stimulated GH secretion from primary rat pituitary cells in a dose-dependant manner. BrdU incorporation was increased in response to CXCL12 addition in GH3 cell culture, indicating CXCL12-induced cell proliferation. CXCL12-dependent phosphorylation of ERK1/2 was also confirmed by western blot analysis, supporting the evidence that MAPK is an intracellular mediator of CXCL12/CXCR4 interaction in GH3 cell proliferation. In conclusion, these results indicate that CXCL12/CXCR4 interaction plays an important role in GH production, secretion, and the proliferation of somatotrophs.

Citing Articles

Research status and prospects of pituitary adenomas in conjunction with neurological and psychiatric disorders and the tumor microenvironment.

Cui S, Chen S, Wu X, Wang Q Front Neurosci. 2024; 18:1294417.

PMID: 38716256 PMC: 11075501. DOI: 10.3389/fnins.2024.1294417.


Pituitary stem cells: past, present and future perspectives.

Perez Millan M, Cheung L, Mercogliano F, Camilletti M, Chirino Felker G, Moro L Nat Rev Endocrinol. 2023; 20(2):77-92.

PMID: 38102391 PMC: 10964491. DOI: 10.1038/s41574-023-00922-4.


The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.

Derwich A, Sykutera M, Brominska B, Rubis B, Ruchala M, Sawicka-Gutaj N Int J Mol Sci. 2023; 24(13).

PMID: 37446128 PMC: 10341524. DOI: 10.3390/ijms241310952.


Tumour microenvironment and pituitary tumour behaviour.

Marques P, Korbonits M J Endocrinol Invest. 2023; 46(6):1047-1063.

PMID: 37060402 DOI: 10.1007/s40618-023-02089-1.


An expression and function analysis of the CXCR4/SDF-1 signalling axis during pituitary gland development.

Gonzalez-Meljem J, Ivins S, Andoniadou C, Le Tissier P, Scambler P, Martinez-Barbera J PLoS One. 2023; 18(2):e0280001.

PMID: 36800350 PMC: 9937476. DOI: 10.1371/journal.pone.0280001.